NNVC - NanoViricides, Inc. | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical NNVC - NanoViricides, Inc.

Previous 10 Next 10

To: donpat who wrote (16)	7/17/2005 5:14:56 PM
From: jmhollen	of 12870

The email is probably the best route. Many CEOs don't read the Boards, so they can claim "plausible deniability" if someone gets their 'nips' in the SEC wringer.... John :-) .

Share	RecommendKeepReply Mark as Last Read

To: donpat who wrote (16)	7/19/2005 4:12:15 AM
From: Max2442	of 12870

Donpat I received your information and am looking forward to tomorrow. I have my limit order in. As you know we have been friends long enough to trust the others judgement. My connections come and go here so I am trusting on your DD and Jim's knowledge. Ah another restless night and perfect for DD. Thanks to both of you. Hopefully I will fill tomorrow along with ACHI and join the party. TIA Max

Share	RecommendKeepReply Mark as Last Read

From: archimedest	7/19/2005 10:38:22 AM
	of 12870

Looks like word is starting to get out as the price slowly climbs and larger blocks are being put through. Anyone know why the quotes on Pink Sheets.com don't appear? I wonder if it has anything to do with their pending move to the otc market?

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: archimedest who wrote (19)	7/19/2005 12:49:36 PM
From: jmhollen	of 12870

The same thing happened to HISC today, and the day-flippers and wienies shorted/sold causing a big dip, ...now recovering. Per Pinksheets.com, they supposedly sent out notifications for comapnies to update their Form-211, or whatever, and if they didn't get them by yesterday they crap-canned their quotes. I'm betting that the "..notification.." was some measley, dumbass email that was worded in a manner that got no one's attention. You might want to call NNVC and gig them about it. John :-) .

Share	RecommendKeepReply Mark as Last Read

From: donpat	7/19/2005 1:38:05 PM
	of 12870

Purdue focuses on cancer research 11:44 AM July 19, 2005 Associated Press Purdue University is creating a new cancer research center where scientists from wide-ranging fields will exchange ideas to develop powerful new therapies. The Oncological Sciences Center announced today eventually will be located at Purdue’s Discovery Park research complex in West Lafayette, where faculty members work on new technologies that can be spun off into biotech companies. The oncology center is one of four newly created Discovery Park centers that will receive $2.5 million each over the next three years under a $10 million gift from the Lilly Endowment. Marietta Harrison, the center’s interim director, said scientists, engineers and experts in communication and human behavior will come together under its aegis to work on ideas for early detection, prevention and treatment of cancer. A key part of the interdisciplinary approach will be nanotechnology, which involves manipulating single atoms and molecules to create tiny machines and devices. Already, Harrison said Purdue researchers are working on projects aimed at spotting tiny tumors and distinguishing normal cells from cancer cells. Early tumor detection can allow doctors to stop cancer in patients before it spreads. The center also will fund a nanotech project that researchers hope can use tiny, constructed “particles” that, when injected into a patient, would be capable of seeking out cancer cells and injecting them with a drug that kills them. “You need all kinds people with different kinds of expertise to put something like that together,” Harrison said. “It’s engineers and biologists and now chemists — so you can see how hugely important the interdisciplinary approach is going to be.” The new center’s projects will be scattered across Purdue’s campus for now, but fund-raising is under way to build a high-tech home for the center at Discovery Park, she said. Harrison said the center’s projects might use laboratory space at the park’s Bindley Biosciences Center and the Birck Nanotechnology Center, which opens Oct. 8. David Johnson, the chief executive of BioCrossroads, a public-private partnership working to invigorate Indiana’s life sciences industry, said the new Purdue center will spur the state’s efforts to create technology-based, high-growth businesses. “Two years ago when we did a targeting study of the best areas for Indiana’s life sciences future, cancer research came up time and again as one of the most promising pursuits we could have as a state,” Johnson said. “Seeing Purdue come into this is very, very exciting.” Over the past few years, Discovery Park has attracted more than $109 million in sponsored research and $100 million in donations for building construction. Research conducted at the park has helped form eight startup companies. indystar.com

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: donpat who wrote (21)	7/19/2005 4:43:07 PM
From: jmhollen	of 12870

I picked up another 10K today. "..S'pensive.." stuff, these h'yar NNVC beans....... John :-) .

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: jmhollen who wrote (22)	7/19/2005 4:50:16 PM
From: donpat	of 12870

Indeed! My (our) usual method is to get in when there are two or three zeros to the right of the decimal place. In this case it didn't happen! I don't think they gave us that opportunity! We must make hay while the sun shines and it is shining bright on NNVC, IMHO!

Share	RecommendKeepReply Mark as Last Read

From: donpat	7/19/2005 10:27:01 PM
	of 12870

UCLA Chemists Create Nano Valve Date: July 15, 2005 Contact: Stuart Wolpert ( stuartw@college.ucla.edu ) Phone: 310-206-0511 UCLA chemists have created the first nano valve that can be opened and closed at will to trap and release molecules. The discovery, federally funded by the National Science Foundation, will be published July 19 in the Proceedings of the National Academy of Sciences. "This paper demonstrates unequivocally that the machine works," said Jeffrey I. Zink, a UCLA professor of chemistry and biochemistry, a member of the California NanoSystems Institute at UCLA, and a member of the research team. "With the nano valve, we can trap and release molecules on demand. We are able to control molecules at the nano scale. "A nano valve potentially could be used as a drug delivery system," Zink said. "The valve is like a mechanical system that we can control like a water faucet," said UCLA graduate student Thoi Nguyen, lead author on the paper. "Trapping the molecule inside and shutting the valve tightly was a challenge. The first valves we produced leaked slightly." "Thoi was a master nano plumber who plugged the leak with a tight valve," Zink said. This nano valve consists of moving parts — switchable rotaxane molecules that resemble linear motors designed by California NanoSystems Institute director Fraser Stoddart's team — attached to a tiny piece of glass (porous silica), which measures about 500 nanometers, and which Nguyen is currently reducing in size. Tiny pores in the glass are only a few nanometers in size. "It's big enough to let molecules in and out, but small enough so that the switchable rotaxane molecules can block the hole," Zink said. The valve is uniquely designed so one end attaches to the opening of the hole that will be blocked and unblocked, and the other end has the switchable rotaxanes whose movable component blocks the hole in the down position and leaves it open in the up position. The researchers used chemical energy involving a single electron as the power supply to open and shut the valve, and a luminescent molecule that allows them to tell from emitted light whether a molecule is trapped or has been released. Switchable rotaxanes are molecules composed of a dumbbell component with two stations between which a ring component can be made to move back and forth in a linear fashion. Stoddart, who holds UCLA's Fred Kavli Chair in nanosystems sciences, has already shown how these switchable rotaxanes can be used in molecular electronics. Stoddart's team is now adapting them for use in the construction of artificial molecular machinery. "The fact that we can take a bistable molecule that behaves as a switch in a silicon-based electronic device at the nanoscale level and fabricate it differently to work as part of a nano valve on porous silica is something I find really satisfying about this piece of research," Stoddart, said. "It shows that these little pieces of molecular machinery are highly adaptable and resourceful, and means that we can move around in the nanoworld with the same molecular tool kit and adapt it to different needs on demand." In future research, they will test how large a hole they can block, to see whether they can get larger molecules, like enzymes, inside the container; they are optimistic. The research team also includes Hsian-Rong Tseng, a former postdoctoral scholar in chemistry who is now an assistant professor of molecular and medical pharmacology in UCLA's David Geffen School of Medicine; Paul Celestre, a former undergraduate student in Stoddart's laboratory; Amar Flood, a former UCLA researcher in Stoddart's supramolecular chemistry group who is now an assistant professor of chemistry at Indiana University; and Yi Liu, a former UCLA graduate student who is now a postdoctoral scholar at the Scripps Research Institute in La Jolla. "Our team and Fraser's have very different areas of expertise," Zink said. "By combining them and working together we were able to make something new that really works." Stoddart has noted that it is only in the past 100 years that humankind has learned how to fly. Prior to the first demonstration of manned flight, there were many great scientists and engineers who said it was impossible. "Building artificial molecular machines and getting them to operate is where airplanes were a century ago," Stoddart said. "We have come a long way in the last decade, but we have a very, very long way to go yet to realize the full potential of artificial molecular machines." The nano valve is much smaller than living cells. Could a cell ingest a nano valve combined with bio-molecules, and could light energy then be used to release a drug inside a cell? Stay tuned. newsroom.ucla.edu

Share	RecommendKeepReply Mark as Last Read

From: Lateott	7/20/2005 12:02:57 PM
	of 12870

Hey Guys, Not trying to bash or anything of that nature. But are we concerned about the phrase "...has exclusive license in perpetuity for technologies developed by Theracour Pharma..."? Only reason I ask is that I'm still licking my fresh wounds from HTDS. Are we aware of any termination clauses... etc? Any thoughts would be appreciated? Thanks, Lateott

Share	RecommendKeepReply Mark as Last Read Read Replies (1)

To: Lateott who wrote (25)	7/20/2005 2:21:27 PM
From: donpat	of 12870

My thoughts on Theracour Pharma. The US patent issued to "Inventors: Watterson; Arthur C. (Nashua, NH); Danprasert; Kunya (Bangkapi, TH); Diwan; Anil (West Haven, CT)" I think that Theracour Pharma was set up to market that patent: Message 21480742 Diwan is the only inventor now at NNVC. He is also a principle at Theracour Pharma: "Anil and his partners have formed a new company, TheraCour Pharma, Inc., with private investor financing to commercialize these materials and also to develop new drugs based on them." Message 21480615 It looks to me that this approach rewards all inventors for the invention by the royalties received and split however agreed upon, likely equally among the three - the three in Theracour, while the vehicle to commercialize the stuff is NNVC with but one inventor in the picture - Diwan - along with shareholders who will be rewarded as NNVC prospers. It could well have been the case that while Diwan was keen to get involved in the commercialization opportunities the other inventors were not, for whatever reasons - perhaps they preferred to stay wherever they are presently, like in the academic community, perhaps. As I said - this is my take. The company could, and should, perhaps, clarify this question fully. Especially regarding any cancellation provisions of this perpetual licence by Theracour Pharma. As you said, once bitten, twice shy!!!

Share	RecommendKeepReply Mark as Last Read Read Replies (2)